全文获取类型
收费全文 | 3956篇 |
免费 | 425篇 |
国内免费 | 252篇 |
专业分类
儿科学 | 83篇 |
妇产科学 | 91篇 |
基础医学 | 245篇 |
口腔科学 | 1篇 |
临床医学 | 315篇 |
内科学 | 1293篇 |
皮肤病学 | 7篇 |
神经病学 | 6篇 |
特种医学 | 325篇 |
外国民族医学 | 3篇 |
外科学 | 724篇 |
综合类 | 546篇 |
现状与发展 | 2篇 |
预防医学 | 98篇 |
眼科学 | 1篇 |
药学 | 143篇 |
1篇 | |
中国医学 | 47篇 |
肿瘤学 | 702篇 |
出版年
2024年 | 14篇 |
2023年 | 133篇 |
2022年 | 212篇 |
2021年 | 244篇 |
2020年 | 256篇 |
2019年 | 194篇 |
2018年 | 130篇 |
2017年 | 189篇 |
2016年 | 204篇 |
2015年 | 185篇 |
2014年 | 258篇 |
2013年 | 208篇 |
2012年 | 201篇 |
2011年 | 221篇 |
2010年 | 212篇 |
2009年 | 169篇 |
2008年 | 216篇 |
2007年 | 159篇 |
2006年 | 190篇 |
2005年 | 169篇 |
2004年 | 130篇 |
2003年 | 114篇 |
2002年 | 101篇 |
2001年 | 84篇 |
2000年 | 94篇 |
1999年 | 63篇 |
1998年 | 52篇 |
1997年 | 31篇 |
1996年 | 35篇 |
1995年 | 34篇 |
1994年 | 23篇 |
1993年 | 17篇 |
1992年 | 12篇 |
1991年 | 7篇 |
1990年 | 12篇 |
1989年 | 15篇 |
1988年 | 10篇 |
1987年 | 5篇 |
1986年 | 9篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有4633条查询结果,搜索用时 9 毫秒
101.
While transjugular intrahepatic portosystemic shunt (TIPS) is a common therapy for cirrhotic patients with diuretic-resistant or diuretic-refractory ascites, some patients are unsuitable for the procedure for technical or medical reasons. We report our experience with the use of chronic intravenous albumin infusions to achieve diuresis in this difficult patient population and review the historic experience of chronic albumin infusions as a treatment for ascites. Nineteen patients with cirrhosis and diuretic-resistant or diuretic-refractory ascites who were deemed unsuitable for TIPS received outpatient intravenous albumin infusions (50 g) weekly for at least 4 weeks. The following endpoints were retrospectively recorded: serum sodium, serum creatinine, blood urea nitrogen, hematocrit, bilirubin, albumin, international normalized ratio, body weight, and Model for End-stage Liver Disease (MELD) score. The contraindicatoins for TIPS included the following: portal vein thrombosis, two; advanced age, one; encephalopathy, nine; hyperbilirubinemia, five; and other, two. Compared to pretreatment, posttreatment weight decreased in 17 patients, remained unchanged in 0 patients, and increased in 2 patients. The overall mean change in body weight (before vs. after therapy) was 8 lb (P < 0.05). The only significant change in biochemistries was an increase in serum albumin from 2.5 g/dl before therapy to 3.5 g/dl after therapy (P < 0.05). We conclude that (1) recurrent intravenous weekly albumin infusions resulted in significant loss of edema and ascites as measured by loss of body weight, and (2) clinicians may want to consider chronic albumin infusions for selected patients with refractory ascites who are not candidates for TIPS. 相似文献
102.
Jie Zhou Weiwen Shen Xiaojing He Jing Qian Shiyuan Liu Guanzhen Yu 《International journal of clinical and experimental pathology》2015,8(9):9863-9874
Prdx1 is an important member of peroxiredoxins (Prdxs) regulating various cellular signaling and differentiation. Prdx1 confers an aggressive survival phenotype of cancer cells and drug-resistance, yet its role in hilar cholangiocarcinoma is not fully investigated. In present study, we detected the expression profile of Prdx1 in 88 hilar cholangiocarcinoma by tissue arrays and immunohistochemistry. Prdx1 level was down-regulated by specific Prdx1-shRNA in vitro and the possible mechanism was investigated. Overexpression of Prdx1 was observed in 53 of 88 cases (60.2%). Prdx1 expression was significantly associated with tumor invasion, nodal metastasis, advanced disease stage. Down-regulation of Prdx1 inhibited cell proliferation and colony formation of QBC939 cells and reduced the level of SNAT1 expression. Patients with Prdx1 overexpression had a shorter disease-free survival and overall survival than those without Prdx1 expression. Multivariate analysis showed that Prdx1 was an independent prognostic factor for patients with hilar cholangiocarcinoma. The data indicate that Prdx1 may contribute to the development and progression of hilar cholangiocarcinoma, partially through regulating SNAT1 expression, and may be used as a biomarker in predicting the outcome of patients with hilar cholangiocarcinoma. 相似文献
103.
Jingjing Li Beibei Gao Zufa Huang Tong Duan Daiqiang Li Sheng Zhang Yujun Zhao Lian Liu Qiang Wang Zhizhao Chen Ke Cheng 《International journal of clinical and experimental pathology》2015,8(8):9512-9516
MircroRNA functions as a tumor suppressor or a promoter in cholangiocarcinoma (CCA). Researchers have found that miR-203 functioned as tumor suppressor in many types of cancer. However, the role of miR-203 that plays in CCA remains to be clarified. We aimed to detect the expression level and the prognostic significance of miR-203 in CCA tissues. qRT-RCR was performed to examine the miR-203 expression levels in CCA tissue specimens and corresponding normal tissues. Our findings suggest that miR-203 expression was an independent poor prognostic factor for CCA patient overall survival. Therefore, miR-203 may serve as a valuable prognostic marker and promising treatment target for CCA. 相似文献
104.
目的:探讨肝外胆管癌的临床病理特点及预后分析。方法:选取2007年1月至2013年1月收治的150例肝外胆管癌患者,给予手术治疗,对患者术后的临床病理特点进行回顾性统计,选择Kaplan-Meier方法分析病理与预后的联系。结果:经过分析后得知,肝外胆管癌患者的1年生存率70.6%、2年生存率18.0%、3年生存率4.0%,平均生存时间18.5月。姑息性手术与根治性手术的生存率存在明显差异( P<0.05)。另外,肝管周围组织浸润阴性者预后效果明显优于阳性者( P<0.05)。肿瘤分化程度越好,患者预后效果越好。结论:针对肝外胆管癌患者,其术后预后因素主要包含肿瘤分化程度、肿瘤浸润和根治性手术,临床治疗时应考虑这些预后因素。 相似文献
105.
Nontumoral portal vein thrombosis (PVT) is an increasingly recognized complication in patients with cirrhosis. Substantial evidence shows that portal flow stasis, complex thrombophilic disorders, and exogenous factors leading to endothelial dysfunction have emerged as key factors in the pathogenesis of PVT. The contribution of PVT to hepatic decompensation and mortality in cirrhosis is debatable; however, the presence of an advanced PVT increases operative complexity and decreases survival after transplantation. The therapeutic decision for PVT is often determined by the duration and extent of thrombosis, the presence of symptoms, and liver transplant eligibility. Evidence from several cohorts has demonstrated that anticoagulation treatment with vitamin K antagonist or low molecular weight heparin can achieve recanalization of the portal vein, which is associated with a reduction in portal hypertension-related events and improved survival in cirrhotic patients with PVT. Consequently, interest in direct oral anticoagulants for PVT is increasing, but clinical data in cirrhosis are limited. Although the most feared consequence of anticoagulation is bleeding, most studies indicate that anticoagulation therapy for PVT in cirrhosis appears relatively safe. Interestingly, the data showed that transjugular intrahepatic portosystemic shunt represents an effective adjunctive therapy for PVT in cirrhotic patients with symptomatic portal hypertension if anticoagulation is ineffective. Insufficient evidence regarding the optimal timing, modality, and duration of therapy makes nontumoral PVT a challenging consequence of cirrhosis. In this review, we summarize the current literature and provide a potential algorithm for the management of PVT in patients with cirrhosis. 相似文献
106.
107.
108.
109.
Sasidharan Rajesh Tom George Cyriac Abby Philips Rizwan Ahamed Sandeep Kumbar Narain Mohan Meera Mohanan Philip Augustine 《World journal of gastroenterology : WJG》2020,26(37):5561-5596
More than five decades after it was originally conceptualized as rescue therapy for patients with intractable variceal bleeding, the transjugular intrahepatic portosystemic shunt(TIPS) procedure continues to remain a focus of intense clinical and biomedical research. By the impressive reduction in portal pressure achieved by this intervention, coupled with its minimally invasive nature, TIPS has gained increasing acceptance in the treatment of complications of portal hypertension. The early years of TIPS were plagued by poor long-term patency of the stents and increased incidence of hepatic encephalopathy. Moreover, the diversion of portal flow after placement of TIPS often resulted in derangement of hepatic functions, which was occasionally severe. While the incidence of shunt dysfunction has markedly reduced with the advent of covered stents, hepatic encephalopathy and instances of early liver failure continue to remain a significant issue after TIPS. It has emerged over the years that careful selection of patients and diligent post-procedural care is of paramount importance to optimize the outcome after TIPS. The past twenty years have seen multiple studies redefining the role of TIPS in the management of variceal bleeding and refractory ascites while exploring its application in other complications of cirrhosis like hepatic hydrothorax, portal hypertensive gastropathy, ectopic varices, hepatorenal and hepatopulmonary syndromes, non-tumoral portal vein thrombosis and chylous ascites. It has also been utilized to good effect before extrahepatic abdominal surgery to reduce perioperative morbidity and mortality. The current article aims to review the updated literature on the status of TIPS in the management of patients with liver cirrhosis. 相似文献
110.